不同剂量辛伐他汀治疗冠心病合并高脂血症的效果及安全性对比

目的观察和分析不同剂量辛伐他汀治疗冠心病合并高脂血症患者的临床效果和安全性。方法选取2012年6月~2013年6月本院收治的冠心病合并高脂血症患者120例,随机分为A组64例,B组56例。在常规治疗基础上,A组给予辛伐他汀40 mg/d,B组给予辛伐他汀20 mg/d,疗程为12周。比较两组治疗前和治疗后8、12周的血脂水平、血脂达标率及不良反应发生率。结果两组治疗后8周TC比较差异有统计学意义（P〈0.05）。两组治疗后12周TC、TG、LDL-C和HDL-C比较差异有统计学意义（P〈0.05）。A组TC达标率为75.00%,明显高于B组的50.00%,差异有统计学意义（P〈0.05）。A组LDL-C达标率为76.56%,明显高于B组的64.28%,差异有统计学意义（P〈0.05）。A组不良反应发生率为10.94%,B组不良反应发生率为8.93%,两组比较差异无统计学意义（P〉0.05）。结论在常规药物治疗基础上,采用辛伐他汀40 mg/d治疗冠心病合并高脂血症患者的效果优于20 mg/d,且安全性较高,值得临床推广应用。

Effect and safety comparison of different doses of simvastatin in the treatment for patient with coronary heart disease combined with hyperlipidemia

Objective To observe and analyze clinical effect and safety of different doses of simvastatin in the treatment for patient with coronary heart disease combined with hyperlipidemia.Methods 120 patients with coronary heart disease combined with hyperlipidemia were chosen and randomly divided into group A with 64 cases and group B with 56 cases.On the basis of routine treatment,simvastatin 40 mg/d was used in group A,simvastatin 20 mg/d was used in group B,treatment course was 12 weeks.Lipid level,lipid standard rate before treatment,after treatment of 8 and 12 weeks and incidence rate of adverse reaction in two groups was compared respectively.Results After treatment of 8 weeks,TC in two groups was compared,with statistical difference（P0.05）.After treatment of 12 weeks,TC,TG,LDL-C and HDL-C in two groups was compared respectively,with statistical difference（P0.05）.TC standard rate in group A was 75.00%,significantly higher than that in group B（50.00%）,with statistical difference（P0.05）.LDL-C standard rate in group A was 76.56%,significantly higher than that in group B（64.28%）,with statistical difference（P0.05）.Incidence rate of adverse reaction in group A and group B was 10.94% and 8.93% respectively,with no statistical difference（P0.05）. Conclusion On the basis of routine treatment,simvastatin 40 mg/d in the treatment of patient with coronary heart disease combined with hyperlipidemia has better effect than simvastatin 20 mg/d.It has high safety,which is worthy of clinical promotion and application.